Abstract:Activation of mineralocorticoid receptors (MR) by its agonist aldosterone induces several unwanted processes like inflammation, fibrosis, increase of blood pressure and ventricular hypertrophy. Inversely, the blockade of MR is known as a highly efficacious therapy in chronic heart failure and arterial hypertension. Therapy with currently approved MR antagonists is often limited due to side effects. Recently, new highly selective, non-steroidal aldosterone antagonists such as finerenone have been developed. To investigate the effects of finerenone on progressive cardiac hypertrophy the transverse aortic constriction (TAC) model was used. C57BL/6 male mice underwent a TAC-operation and were treated daily by oral gavage with finerenone (fin; 10 mg/kg/d), eplerenone (200 mg/kg/d) or vehicle (veh). The treatment started one week before the TAC-operation, and was continued 4 weeks postoperative. To examine the efficacy of finerenone on myocardial wall thickening echocardiography was performed one week before and 4 weeks after TAC and left ventricular mass (LVM) was calculated. Furthermore, gene expression analysis in heart and kidney were carried out to investigate molecular mechanisms. TAC-operated mice treated with finerenone showed a significant lower LVM relative to body weight compared with vehicle-treated mice (fin: 3.89 mg/g; veh: 4.32 mg/g; p<0.05). Also the percentage increase of LVM four weeks after TAC was significantly lower in finerenone-treated animals than in vehicle-treated mice (fin: +37.16 %, veh: +52.9 %, p<0.05). Furthermore, markers of pathological hypertrophy like atrial natriuretic factor (ANF) and β-myosin heavy chain (β-MyHC) were measured in the left ventricle, and showed a higher expression in vehicle-treated than finerenone-treated animals. Treatment with eplerenone did not significantly reduce cardiac hypertrophy after 4 weeks post TAC. In conclusion, these data show for the first time beneficial effects of the new non-steroidal MR-antagonist finerenone on LVM development in a TAC-model. The distinct actions of finerenone when compared to eplerenone may result from different MR-blocking properties.

Eplerenone regulates hypertrophy in heart failure by microRNA-208 a inhibiting on THRAP 1

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Eplerenone Prevents Atrial Fibrosis Via the TGF-β Signaling Pathway

Effects of Eplerenone on Vascular Remodeling in Spontaneously Hypertensive Rats not Related with Blood Pressure

Effects of Eplerenone on Renal Expression of Renin Receptor in Aldosterone-Infused Rats

Eplerenone inhibits atrial fibrosis in mutant TGF-β1 transgenic mice

PS-B03-9: EPLERENONE PREVENTS CARDIAC FIBROSIS BY INHIBITING ANGIOGENESIS IN UNILATERAL URINARY OBSTRUCTION RATS

Eplerenone in Combination with ACE Inhibitor Reduces Post-Myocardial Infarction LV Remodeling and Maintains Function

Eplerenone Potentiates Protective Effects of Amlodipine Against Cardiovascular Injury in Salt-Sensitive Hypertensive Rats.

Alteration of RhoA Prenylation Ameliorates Cardiac and Vascular Remodeling in Spontaneously Hypertensive Rats.

Abstract 007: Effects Of Finerenone - A Novel Non-steroidal Mineralocorticoid Receptor Antagonist In A Model Of Pressure Overload-induced Cardiac Hypertrophy

Eplerenone Inhibits Aldosterone-Induced CRP Generation in Rat Vascular Smooth Muscle Cells by Regulating the MR-ROS-ERK1/2 Signal Pathway

A Meta-analysis on efficacy and safety of eplerenone in treatment of hypertension

Damage of Aldosterone on the Heart of the Rat with Spontaneously Hypertensive and Protective Effect of Eplerenone

Novel Effect of Mineralocorticoid Receptor Antagonism to Reduce Proinflammatory Cytokines and Hypothalamic Activation in Rats With Ischemia-Induced Heart Failure

Angiotensin-converting Enzyme Inhibitory Peptide Attenuates Cardiac Hypertrophy Associated with ACE2/Ang (1-7)/Masr Axis and PKC81 Pathway

Eplerenone inhibits UUO-induced lymphangiogenesis and cardiac fibrosis by attenuating inflammatory injury

Anti‐inflammatory Effects of Eplerenone on Viral Myocarditis

599 APOCYNIN AND EPLERENONE ATTENUATES OXIDATIVE STRESS AND CARDIAC FIBROSIS IN ANGIOTENSIN II-INDUCED CARDIAC DIASTOLIC DYSFUNCTION

Prostaglandin E1 Attenuates AngII-induced Cardiac Hypertrophy Via EP3 Receptor Activation and Netrin-1upregulation

Effect of eplerenone on cognitive impairment in spontaneously hypertensive rats